P97: Cost of illness and economic burden of early Alzheimer’s disease: a systematic review
Richard Lawson, MSc¹, Weiguang Xue, MSc², Adam Lloyd, MPhil², Christina-Jane Crossman-Barnes, MSc³, Rebekah Fong, MSc³
(1) AstraZeneca, US (2) QuintilesIMS, UK (3) University of East Anglia, UK

P98: Challenges in Optimising Real World Evidence for Alzheimer’s Disease
Catherine Reed, PhD¹, Frederic de Reydet de Vulpillieres, MSc², John Gallacher, PhD³, and the ROADMAP consortium
(1) Eli Lilly and Company Limited, Windlesham, UK (2) Novartis Pharma AG, Basel, Switzerland (3) University of Oxford, UK

P99: Dependence Scale to Assess the Cost-Consequences of Alzheimer’s Disease Treatments
Joshua A. Roth, PhD, MHA¹, Joshua T. Cohen, PhD², Peter J. Neumann, ScD², Carolyn W. Zhu, PhD³, Yaakov Stern, PhD⁴, Sean D. Sullivan, PhD⁵
¹Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
²Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA
³Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
⁴Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York, NY, USA
⁵Department of Pharmacy, University of Washington, Seattle, WA, USA